Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.

about

Dosing de novo combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers.

P2860

Q36998239-0C3ED103-A4E3-471F-8EAA-946911B28A93

P2860

Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.

Item

http://www.wikidata.org/entity/Q35770263

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Dual antiangiogenic inhibition ...... ts with advanced solid tumors.

@ast

Dual antiangiogenic inhibition ...... ts with advanced solid tumors.

@en

type

Item

label

Dual antiangiogenic inhibition ...... ts with advanced solid tumors.

@ast

Dual antiangiogenic inhibition ...... ts with advanced solid tumors.

@en

prefLabel

Dual antiangiogenic inhibition ...... ts with advanced solid tumors.

@ast

Dual antiangiogenic inhibition ...... ts with advanced solid tumors.

@en

P1476

Dual antiangiogenic inhibition ...... ts with advanced solid tumors.

@en

P2093

David S Hong

http://www.w3.org/2001/XMLSchema#string

Gerald S Falchook

http://www.w3.org/2001/XMLSchema#string

Jennifer J Wheler

http://www.w3.org/2001/XMLSchema#string

Kristin Parkhurst

http://www.w3.org/2001/XMLSchema#string

Mei Huang

http://www.w3.org/2001/XMLSchema#string

Quan Lin

http://www.w3.org/2001/XMLSchema#string

Ralph Zinner

http://www.w3.org/2001/XMLSchema#string

Sarina A Piha-Paul

http://www.w3.org/2001/XMLSchema#string

Siqing Fu

http://www.w3.org/2001/XMLSchema#string

Yunfang Jiang

http://www.w3.org/2001/XMLSchema#string

P2860

Survival of cancer cells is maintained by EGFR independent of its kinase activity

Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

Sunitinib therapy for melanoma patients with KIT mutations.

Tumor angiogenesis: therapeutic implications

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Sorafenib in advanced hepatocellular carcinoma

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

P2888

s10637-014-0176-4

P304

215-224

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10637-014-0176-4

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Razelle Kurzrock

Apostolia Maria Tsimberidou

Aung Naing

Filip Janku

P577

2014-11-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25363205

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

P932

4477529

http://www.w3.org/2001/XMLSchema#string

Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.

about

P2860

P2860

Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P921

P932